Issue 80

EXCLUSIVE: Biomind Labs' relocation to the UK

At yesterday’s PSYCH Symposium, Biomind Labs announced it was relocating from Toronto to Cambridge, recognising the opportunities in Europe’s emerging psychedelic healthcare market.

The UK is home to world-leading research organisations and academic institutions, with Biomind Labs working closely with Cambridge University.

PSYCH was fortunate enough to speak with Biomind Labs’ CEO Alejandro Antalich ahead of the seminal event, for exclusive insight on the company’s strategic relocation.

LANDMARK GATHERING OF PSYCHEDELICS EXECUTIVES AND SCIENTISTS IN LONDON

Ahead of PSYCH Symposium: London 2022, Psychedelic Alpha explored Europe’s emerging ecosystem.

BRAIN SCANNING TECHNOLOGY TO TEST IMPACT OF PSYCHEDELIC HEALTHCARE

Kernel hopes to measure brain activity before, during and after a psychedelic experience to produce quantifiable data.

BUSINESS AND INVESTMENT

Biotechs want to unlock the psychedelics market, but it isn’t simple.

Europe’s first psychedelic drug trial firm to open in London.

Psychedelic patents are broken because the patent system is broken.

Small Pharma to participate at PSYCH Symposium.

PharmaTher is granted patent for ketamine production process.

Novamind to host Bionomics’ trial to treat social anxiety disorder.

SCIENCE AND RESEARCH

Is psilocybin the future of mental health treatments?

Why psychedelic medicines may become a key treatment for PTSD and depression.

REGULATION AND LEGISLATION

New York lawmakers discuss competing psychedelic reform bills.

Colorado governor backs psychedelic medicine reform.

Governor of Connecticut signs bill to create psychedelic medicine programme.